Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Bioton's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0DTR vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, Bioton's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioton Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bioton's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Bioton's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioton (LTS:0DTR) has a Buyback Yield % of 0.00 as of Jul. 20, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Bioton and its competitors. According to the industry distribution chart, Bioton ranks #999999 out of 740 companies in the Biotechnology industry.
Is Bioton's Buyback Yield % too high?
Bioton's current Buyback Yield % is 0.00. Based on the distribution chart, Bioton ranks #999999 out of 740 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Bioton has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Bioton's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bioton ranks #999999 out of 740 companies for Buyback Yield %. This places Bioton in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Bioton and its competitors. Bioton's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioton stock overvalued right now?
Bioton (LTS:0DTR) has a current Buyback Yield % of 0.00. The stock's GF Value™ is zł4.27, compared to a current price of zł3.43 — trading 19.7% below its estimated fair value. The current Buyback Yield % is 0.00. Bioton's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Bioton (LTS:0DTR), the current Buyback Yield % is 0.00 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioton (LTS:0DTR) Overvalued in 2026?
Based on GuruFocus' analysis, Bioton stock appears to be undervalued.
The current stock price of zł3.43 is trading 19.7% below its estimated GF Value™ of zł4.27.
Key valuation signals for LTS:0DTR:
Buyback Yield %: 0.00
GF Value™: zł4.27 vs. price of zł3.43 (19.7% below fair value)
No single metric tells the full story. See the LTS:0DTR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioton SA is a Poland based company engaged in the principal business activity of manufacturing medicines and pharmaceutical preparations and production of pharmaceutical substances. The products of the company include recombinant human insulin in pharmaceutical substance form and as preparations for injections; glimepiride, an oral hypoglycemic drug; and metformin, an oral hypoglycemic drug. Its products line focuses on diet supplements, products for particular nutritional uses and cosmetics dedicated to patients with certain health problems. The group operates in Poland and internationally, of which majority of the revenue is derived from Poland.
68GF Score
Get the complete analysis for LTS:0DTR
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DTR has been successfully added to your 
